Tongce Medical, a prominent player in the dental industry, finds itself at a crossroads as it faces an array of challenges affecting its growth trajectoryWith a relatively low debt-to-equity ratio, robust cash flow, and a high return on equity (ROE), there is speculation about the firm's potential to expand through acquisitions of reputable dental clinics outside its home province of Zhejiang, which could facilitate its growth and livelihoodHistorically, Tongce has been a darling of public investors, even achieving remarkable highs in its stock price in 2021, but currently faces a stark reality, as its market value has plummeted significantly.

Once celebrated for its vigorous growth, Tongce Medical's stock price skyrocketed to an astonishing 422 yuan in 2021, equating to a market cap of over 135 billion yuan

However, currently, the stock languishes at approximately 49 yuan, resulting in a staggering 84% drop compared to its peakThis alarming decline in price can mainly be attributed to the massive exits of institutional investors, primarily triggered by the cessation of new investments from public funds and influenced by new policies on dental implants.

The company has recorded no significant growth in revenue recently, with its Q3 2024 financial results revealing zero growth in income and a 7.4% decline in net profit year-on-yearThe first half of the year showed a comparatively better performance with a revenue increase of 3.5% and a 4.33% rise in net profitNevertheless, the firm’s ROE remains at a reasonable level, close to 12.49% in the first three quarters of 2024.

Historically, the company was quite profitable, boasting an impressive ROE of 29.87% in 2019, though it dropped to 14.06% in 2023. This decrease can largely be blamed on the drop in dental implant prices caused by the government’s bulk purchasing program, which negatively impacted profit margins

Notably, in November 2022, Tongce announced a 20% price reduction for dental implants, which resulted in a 47% increase in the number of implants placed—over 53,000 implants—but the revenue generated from implants only grew by a modest 6.95%, indicating a 27% reduction in pricing per implant.

In comparison, Meihau Medical Group, a competitor listed on the Hong Kong Stock Exchange, faced an even steeper decline in revenue of 42.3% due to the same government purchasing pressure, with gross margins also suffering considerablyThe metrics speak volumes about the overall sentiment within the dental industry, where pressures from price controls and increased competition are paramount.

The trend in revenue growth for Tongce Medical has been starkly downward in recent yearsBetween 2015 and 2021, the firm enjoyed impressive growth, but revenue rates began to decline thereafter

In the years 2022 and beyond, growth rates fell to -2.23%, 4.7%, and 2.21% for 2023 and the first three quarters of 2024. This sustained decrease emphasizes how the impact of government policy is not a fleeting concern but one that is likely to persist.

Additionally, the plunging gross margins are not solely attributable to the price reductions of dental implants but also stem from an increasingly competitive market landscapeFrom a margin of approximately 45% to 46% in 2019 to around 38.53% in 2023, the earnings potential has diminished significantlyIn contrast, Haocen Medical, another A-share dental service company, boasts higher margins, showcasing how competition continues to shape the operational challenges faced by firms within this space.

When viewed over a longer timeline, Tongce’s margins and ratios still remain relatively strong

alefox

However, the slowdown in revenue growth has fostered a reduction in market expectations of the companyHaocen Medical, with a revenue scale only a quarter of Tongce’s, has shown a growth rate that exceeds it significantlyYet, it too faces challenges, with high marketing costs and subsequent reductions in profit margins.

Another entity in this market, the Ruier Group, runs into profitability challenges rooted in higher operating costs due to rent and dentist salariesWith a market capitalization of just over 1.4 billion yuan, its financial reports reflect modest growth but significant declines in net profit, showcasing the broader industry challenge where many players have to contend with similar hurdles.

For Tongce Medical, expansion beyond the provincial borders seems dauntingWhile its historical reputation and brand recognition within Zhejiang facilitate customer acquisition efficiently, the moment it ventures outside this familiar territory, it risks encountering barriers to maintaining these advantages

Many of its current facilities remain concentrated in the province, with demand and revenue significantly tied to this locale.

However, if the company continues to rely solely on expansions within Zhejiang, it risks the chance of oversaturation of the market, which comes with its own set of difficultiesNotably, their dental services in pediatric and orthodontic segments are now showing slight declines, which may become an increasing concern given the nation's declining birth rates, impacting segments critically dependent on younger demographicsNevertheless, its implant revenue shows promising growth, mostly driven by older populations.

Presently, it appears that Tongce’s financial health, indicated by its low debts and good cash flow, could allow for strategic acquisitions outside the Zhejiang province

Yet, there is little evidence of any proactive approach in this directionThere have been indications that the company may diversify into medical technology, but skepticism surrounds the effectiveness of such a strategy.

Furthermore, the recent purchase of land from a controlling shareholder for the development of a dental hospital and a streaming base raises eyebrows, especially in a market flooded with office spacesThe competitive landscape in dental services in urban areas like Beijing is becoming increasingly tough, with marketing strategies reaching a level where outreach strategies have workers stationed at local supermarkets.

For Tongce Medical, the prospect of stagnation looms if it fails to innovate and adaptA mere 2%-5% annual growth could become the new realityWithout considering mergers and acquisitions as a means to tap into new demographic segments or stabilize its revenue base, it might struggle to reclaim the growth it once enjoyed